Ness Ziona, Israel, May 27, 2015 — Mapi Pharma Ltd. announced today that Shavit Capital has led an investment round of $10 million in the company in a Series A financing round that included participation by the company’s chairman and CEO Mr. Ehud Marom. The...
The monthly injection of GA Depot is intended to replace current treatments for RRMS including the daily or thrice-weekly injection of Copaxone® Ness Ziona, Israel, December 17, 2014 — Mapi Pharma Ltd. announced today that the first patient was treated in...
Ness Ziona, Israel, May 27, 2014 —- Mapi Pharma Ltd. (“Mapi” or the “Company”), a developer of high-barrier to entry and high value-added generic drugs, announced today that its US patent for the company’s Glatiramer Acetate Depot has been extended until...
The patent covers the process and preparation of Tapentadol for the treatment of moderate to severe-acute pain Ness Ziona, Israel, June 18, 2013 —- Mapi Pharma Ltd. (Mapi), developer of complex bulk Active Pharmaceutical Ingredients (APIs), generic and...
The patent covers a long acting depot formulation that enables monthly rather than daily treatment regimens for MS patients Ness Ziona, Israel, May 6, 2013 —- Mapi Pharma Ltd. (Mapi), developer of complex bulk Active Pharmaceutical Ingredients (APIs), generic...
The patent covers intermediate compounds and processes for the preparation of Fingolimod Ness Ziona, Israel, February 18, 2014 —- Mapi Pharma Ltd. (“Mapi” or the “Company”), a developer of high-barrier to entry and high value-added generic drugs that include... 